drugset / Trial / NCT07291102
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
Phase 3
Not yet recruiting
96 enrolled
Nationwide Children's Hospital
Children's of Alabama · collabGerman Society of Paediatric Oncology and Hematology (GPOH gGmbH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC amplified MF randomized to the interventional arms A ("Head Start 4") or B (HIT-SKK).
Timeline
- Start
- 2026-07-01
- Primary completion
- 2034-10
- Completion
- 2038-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Etoposide | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | Intravenous |
| Subject | Thiotepa | Other / unclassified | — | — |
| Subject | Vincristine | Small molecule | — | — |